The European Consortium ""Antiviral Therapeutics for Rapid Response Against Pandemic Infectious Diseases"" (AVITHRAPID). The aim of the project is to establish a pipeline of small molecule-based antiviral agents that can be widely used and rapidly developed into therapies against emerging infectious diseases. As part of the project, the consortium intends to test a small molecule against Zika virus in a clinical trial. The European consortium "Antiviral Therapeutics for Rapid Response Against Pandemic Infectious Diseases" AVITHRAPID is part of the EU Horizon research programme call "Pandemic preparedness and response: Broad spectrum anti-viral therapeutics for infectious diseases with epidemic potential". The AVITHRAPID research consortium comprises 18 research institutions and companies from 8 countries, coordinated by the German Fraunhofer-Gesellschaft. AVITHRAPID started in January 2024 with a duration of 54 months .The Swiss Partners in the AVITHRAPID consortium are funded by the Swiss State Secretariat for Education, Research and Innovation SERI.
Company Details
- Founded
- -
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.avithrapid.eu
- Keywords
- Monserrato.
Avithrapid Questions
Avithrapid's website is http://www.avithrapid.eu
Avithrapid's LinkedIn profile is https://www.linkedin.com/company/avithrapid
Avithrapid's industry is
Biotechnology Research
Avithrapid's top competitors are
Fresenius Kabi,
Pathonext Gmbh,
Genolytic Gmbh,
Epitopic Gmbh,
Covend,
Advise Project,
Halotek,
Vaxxinova Diagnostics Gmbh,
Dendropharm Gmbh,
Pluriselect Life Science.
Avithrapid's categories are Biotechnology Research
Avithrapid's founding year is 2024
